Kalbhen D A, Jansen G
Institut für Pharmakologie und Toxikologie, Universität Bonn.
Arzneimittelforschung. 1990 Sep;40(9):1017-21.
A standardized pharmacological model of biochemically induced osteoarthritis in the knee joint of laboratory animals was used for the study of a possible antidegenerative effect of ademetionine (S-adenosyl-methionine, active substance of Gumbaral) in-vivo. Four days after the initial induction of osteoarthritis by 2 intraarticular injections of 0.6 mg sodium iodoacetate into the left knee joint of adult hens, the therapy started with once-weekly intraarticular doses of 0.5 mg, 1.0 mg and 2.0 mg ademetionine over a period of 14 weeks. Quantitative monitoring of the intensity and progression of osteoarthritis was performed every 2 weeks by joint space measurements, topographic-radiological evaluations, and by a macroscopic post-mortem assessment of the joint cartilage and bone. These objective analytical parameters clearly demonstrated that weekly intraarticular doses of 1.0 mg ademetionine significantly reduced the intensity of degenerative processes compared to the placebo (saline) treated joints. The antidegenerative effect of doses of 0.5 mg or 2.0 mg ademetionine were less pronounced and of no statistical significance. Our findings indicate an interesting therapeutic potency of ademetionine in experimental osteoarthritis and confirm the positive clinical observations as well as in-vitro results with this new drug by other researchers.
在实验动物膝关节中，采用一种标准化的生化诱导骨关节炎药理学模型，来研究腺苷蛋氨酸（S-腺苷甲硫氨酸，甘氨酸的活性物质）在体内可能的抗退变作用。在成年母鸡左膝关节内通过两次关节内注射0.6mg碘乙酸钠初步诱导骨关节炎4天后，开始治疗，每周一次关节内注射0.5mg、1.0mg和2.0mg腺苷蛋氨酸，持续14周。每2周通过关节间隙测量、地形放射学评估以及对关节软骨和骨骼的宏观尸检评估，对骨关节炎的强度和进展进行定量监测。这些客观分析参数清楚地表明，与接受安慰剂（生理盐水）治疗的关节相比，每周一次关节内注射1.0mg腺苷蛋氨酸显著降低了退变过程的强度。0.5mg或2.0mg腺苷蛋氨酸剂量的抗退变作用不太明显，且无统计学意义。我们的研究结果表明腺苷蛋氨酸在实验性骨关节炎中具有有趣的治疗潜力，并证实了其他研究人员对这种新药的阳性临床观察结果以及体外实验结果。
